Cargando…

Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data

BACKGROUND: So far only trastuzumab, pembrolizumab and ramucirumab have been approved by the FDA for targeted therapy in gastric cancer (GC). Here we report on potential targeted therapy options for gastric adenocarcinoma based on a novel analysis of “The Cancer Genome Atlas (TCGA)” database. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hescheler, Daniel A., Plum, Patrick S., Zander, Thomas, Quaas, Alexander, Korenkov, Michael, Gassa, Asmae, Michel, Maximilian, Bruns, Christiane J., Alakus, Hakan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305081/ https://www.ncbi.nlm.nih.gov/pubmed/32107691 http://dx.doi.org/10.1007/s10120-020-01045-9

Ejemplares similares

Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence
por: Pasternack, Helen, et al.
Publicado: (2018)

Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas
por: Rehkaemper, Jan, et al.
Publicado: (2020)

Anaplastic thyroid cancer: genome-based search for new targeted therapy options
por: Hescheler, Daniel Alexander, et al.
Publicado: (2022)

GATA binding protein 6 (GATA6) is co-amplified with PIK3CA in patients with esophageal adenocarcinoma and is linked to neoadjuvant therapy
por: Plum, Patrick Sven, et al.
Publicado: (2020)

Targeted Therapy for Adrenocortical Carcinoma: A Genomic-Based Search for Available and Emerging Options
por: Hescheler, Daniel Alexander, et al.
Publicado: (2022)

Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target
por: Loeser, Heike, et al.
Publicado: (2017)

HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma
por: Plum, Patrick Sven, et al.
Publicado: (2019)

Two decades of gastric and gastroesophageal junction cancer surgery
por: Plum, Patrick S., et al.
Publicado: (2023)

Occurrence of High Microsatellite-Instability/Mismatch Repair Deficiency in Nearly 2,000 Human Adenocarcinomas of the Gastrointestinal Tract, Pancreas, and Bile Ducts: A Study From a Large German Comprehensive Cancer Center
por: Quaas, Alexander, et al.
Publicado: (2021)

Extension of resection after positive intraoperative pathology during surgery for gastric and gastroesophageal junction adenocarcinoma: a retrospective cohort study
por: Plum, Patrick S., et al.
Publicado: (2023)

Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma
por: Loeser, Heike, et al.
Publicado: (2020)

Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis
por: Hescheler, Daniel A., et al.
Publicado: (2021)

Claudin 18.2 expression in esophageal adenocarcinoma and its potential impact on future treatment strategies
por: Moentenich, Valeska, et al.
Publicado: (2020)

Fructose-1,6-bisphosphatase 1 (FBP1) is an independent biomarker associated with a favorable prognosis in esophageal adenocarcinoma
por: Damanakis, Alexander, et al.
Publicado: (2022)

Mesothelin expression in esophageal adenocarcinoma and squamous cell carcinoma and its possible impact on future treatment strategies
por: Moentenich, Valeska, et al.
Publicado: (2020)

The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis
por: Simon, Adrian Georg, et al.
Publicado: (2023)

Y Chromosome Loss Is a Frequent Event in Barrett’s Adenocarcinoma and Associated with Poor Outcome
por: Loeser, Heike, et al.
Publicado: (2020)

Upregulation of miR-17-92 cluster is associated with progression and lymph node metastasis in oesophageal adenocarcinoma
por: Plum, Patrick Sven, et al.
Publicado: (2019)

The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma
por: Loeser, Heike, et al.
Publicado: (2019)

Lymphocyte activation gene-3 (LAG3) mRNA and protein expression on tumour infiltrating lymphocytes (TILs) in oesophageal adenocarcinoma
por: Gebauer, Florian, et al.
Publicado: (2020)

Optimized PD-L1 scoring of gastric cancer
por: Schoemig-Markiefka, Birgid, et al.
Publicado: (2021)

PIK3CA and KRAS Amplification in Esophageal Adenocarcinoma and their Impact on the Inflammatory Tumor Microenvironment and Prognosis
por: Essakly, Ahlem, et al.
Publicado: (2019)

Sex-specific prognostic effect of CD66b-positive tumor-infiltrating neutrophils (TANs) in gastric and esophageal adenocarcinoma
por: Quaas, Alexander, et al.
Publicado: (2021)

Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma
por: Schallenberg, Simon, et al.
Publicado: (2020)

Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma
por: Quaas, Alexander, et al.
Publicado: (2019)

Long-Term Postsurgical Outcomes of Neoadjuvant Chemoradiation (CROSS) Versus Chemotherapy (FLOT) for Multimodal Treatment of Adenocarcinoma of the Esophagus and the Esophagogastric Junction
por: Gebauer, Florian, et al.
Publicado: (2023)

Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2020)

Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma
por: Wu, Xiaolin, et al.
Publicado: (2020)

Genomic Characterization of TP53–Wild-Type Esophageal Carcinoma()
por: Quaas, Alexander, et al.
Publicado: (2018)

Short-term outcome of Ivor Lewis esophagectomy following neoadjuvant chemoradiation versus perioperative chemotherapy in patients with locally advanced adenocarcinoma of the esophagus and gastroesophageal junction: a propensity score-matched analysis
por: Plum, Patrick Sven, et al.
Publicado: (2021)

FGFR2-amplified tumor clones are markedly heterogeneously distributed in carcinomas of the upper gastrointestinal tract
por: Albin, Jan, et al.
Publicado: (2022)

High protein and mRNA expression levels of TUBB3 (class III ß-tubulin) are associated with aggressive tumor features in esophageal adenocarcinomas
por: Loeser, Heike, et al.
Publicado: (2017)

Elevated X-linked inhibitor of apoptosis protein (XIAP) expression uncovers detrimental prognosis in subgroups of neoadjuvant treated and T-cell rich esophageal adenocarcinoma
por: Schiffmann, Lars M., et al.
Publicado: (2019)

Cell type‐specific transcriptomics of esophageal adenocarcinoma as a scalable alternative for single cell transcriptomics
por: Krämer, Max, et al.
Publicado: (2020)

Integrin beta1 (ITGB1) as a prognostic marker in esophageal adenocarcinoma
por: Damanakis, Alexander I., et al.
Publicado: (2022)

Combined score of Y chromosome loss and T-cell infiltration improves UICC based stratification of esophageal adenocarcinoma
por: Raters, Verena Maria, et al.
Publicado: (2023)

Integrin alpha V (ITGAV) expression in esophageal adenocarcinoma is associated with shortened overall-survival
por: Loeser, Heike, et al.
Publicado: (2020)

Dissecting the inflammatory tumor microenvironment of esophageal adenocarcinoma: mast cells and natural killer cells are favorable prognostic factors and associated with less extensive disease
por: dos Santos Cunha, Alyne Condurú, et al.
Publicado: (2023)

Trophoblast Cell Surface Antigen 2 (TROP2) as a Predictive Bio-Marker for the Therapeutic Efficacy of Sacituzumab Govitecan in Adenocarcinoma of the Esophagus
por: Hoppe, Sascha, et al.
Publicado: (2022)

Proposal for a definition of "Oligometastatic disease in pancreatic cancer"
por: Damanakis, Alexander I., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tmf5tv21k1rrs86ijo2d1dsgug